There are no Related articles on IMMY.
There are no Transcripts on IMMY.
Wed, Aug. 13, 6:18 PM
Wed, Aug. 13, 5:30 PM
Mon, Jul. 28, 12:45 PM
Tue, May. 20, 12:46 PM
Thu, Apr. 3, 12:45 PM
Dec. 13, 2013, 12:51 PM
Aug. 28, 2013, 1:57 PMImprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions
- Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.
- The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.
- IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."
- Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Aug. 13, 2013, 12:45 PM
Jul. 15, 2013, 12:45 PM
Apr. 18, 2013, 2:31 PM
IMMY vs. ETF Alternatives
Other News & PR